As part of a phase 1 trial of a candidate AIDS vaccine, blood specimens were collected from 168 healthy adult volunteers at minimal or no risk for becoming infected with human immunodeficiency virus type 1 (HIV-l). These specimens were screened for evidence ofHIV-l infection by enzyme immunoassay (EIA) and the Biotech/Du Pont Western blot (n = 168), culture (n = 122), and polymerase chain reaction assay (n = 20). None of the subjects had a positive test result by any of these assays, but 32% had indeterminate Western blot tests, most of which demonstrated a single band of low intensity. The most common bands were p24 (47%), p55 (34%), and p66 (36%); envelope bands were unusual (gp41, 2%; gp120, 2%). No serum specimen collected after 2-11 months from individuals with indeterminate Western blot results was positive by EIA or Western blot. There was 91% agreement in the test results ofthe first and second serum samples when the same lot of Western blot kit was used but only 36% agreement when different lots were used. The Biotech/Du Pont Western blot kit thus frequently yields indeterminate test results in the absence of HI V-Iinfection, the reproducibility of which is subject to lot-to-Iot variability.
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Testing for human immunodeficiency virus type 1 (HN-l)
infection is encouraged for those at high risk and is mandatory for blood and organ donors, for individuals applying for military service, for immigration, and, in many cases, for life and health insurance policies [1] . As routine testing increases, concern has been expressed that the false-positive rate ofHN-l serologic tests might be unacceptably high among populations with a low prevalence of HIV-l infection [2] . Two recent studies conducted in low-risk populations concluded that the false-positive rate for detection of HN-l infection in the setting of a positive enzyme immunoassay (EIA) and Western blot (WB) was extremely low [3, 4] . However, many studies have noted the occurrence of indeterminate WB tests that have one or more bands but do not meet the criteria necessary for a positive result [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Indeterminate WB results lead to considerable confusion and anxiety because their meaning is unclear. Informed consent wasobtained from all subjects, and experimentation guidelines of the authors' institutions were followed.
Financial support: AI-62515 (National Institutes of Health As part of a multicentered phase 1 safety and immunogenicity trial of a candidate AIDS vaccine, we screened healthy adults at minimal or no risk for acquiring HIV-l infection. A surprisingly high percentage, although negative for HIV-l antibody by commercial EIA, had an indeterminate WB result. Additional WB testing in individuals followed prospectively for 2-11 months allowed us to characterize the pattern of their test results over time and to determine the degree of lot-to-lot variability among different WB kits.
Materials and Methods
Participating sites. Six institutions, designated as AIDS vaccine evaluation units (AVEUs), participated in this study as part of an AIDS vaccine trial. They were located at the Johns Hopkins University School of Hygiene and Public Health (Baltimore) and the Schools of Medicine of Baylor (Houston), Marshall (Huntington, WV), Maryland (Baltimore), Rochester (NY), and Vanderbilt (Nashville, TN) universities. The central laboratory was located at Georgetown University (Washington, DC).
Subjects. Healthy volunteers 18-55 years old were screened between December 1987 and April 1988 to determine their eligibility to participate in an AIDS vaccine trial [14] . Volunteers were excluded if they had a history of behavior that placed them at risk for acquiring HIV-l infection, of hepatitis B virus (HBV) infection or vaccination, or of blood product transfusion within the preceding 6 months. Eligible volunteers were tested by EIA and WB for anti-HIV-l antibodies (n = 168), by HIV-l P 24 antigen test (n = 168), and by HIV-l culture (n = 122). They were also screened for serologic markers of HBV.
Volunteers who had an indeterminate WB result were ineligible to participate in the vaccine trial, regardless of negative tests for HIV-l infection by EIA, p24 antigen test, and HIV-l culture. Thirtythree (62 %) of 53 WB-indetemrinate volunteers agreed to be retested 1"\.16 months later by EIA, WB, and p24 antigen test for HIV-l and to be screened for antibodies to human immunodeficiency virus type 2 (HIV-2) and human T-celilymphotropic virus type I (HTLV-n. Polymerase chain reaction (PCR) for HIV-l was also done on peripheral blood mononuclear cells (PBMCs) from 20 WB-indetemrinate volunteers. During the same period, serial blood samples were collected from study subjects with negative WB results who received placebo or hepatitis B vaccine in the AIDS vaccine trial.
HW-l serologic assays. Serum samples were tested for HIV-l antibody and p24 antigen by EIA kits (HIV-EIA and HTLV-ill antigen EIA; Abbott Laboratories, North Chicago). WB assays were done with the Biotech/Du Pont kit (Biotech Research Laboratories, Rockville, MD, and Du Pont, Wilmington, DE) and interpreted according to manufacturers' guidelines [6] . Briefly, bands on the WB were assigned an intensity of +/-(less than the intensity of the p24 band on the weakly reactive control strip), + (equal to or greater than the intensity of the p24 band on the weakly reactive control strip but less than that on the strongly reactive control strip), or ++ (equal to or greater than the intensity of the p24 band on the strongly reactive control strip). A WB was defined as positive if it had bands with a + or ++ intensity at p24, p31, and one of the envelope bands gp41, gp120, or gp160. A WB was indeterminate if it had one or more virus-specific bands of any intensity but did not satisfy the criteria for a positive interpretation. The EIA and WB tests were performed at the AVEUs where the respective serum specimens were collected. Paired serum samples were also tested by WB at the centrallaboratory. To control for observer variability, one investigator at each of the AVEUs and the central laboratory read the WB tests.
HW-l cultures.
Virus was isolated at the AVEUs by a previously described method [15] . Freshly collected PBMCs were separated from heparinized blood and suspended in RPMI 1640 medium containing fetal calf serum, glutamine, penicillin, streptomycin, and interleukin-2. They were routinely cultivated with normal human phytohemagglutinin-stimulated PBMCs. Cultures were assayed for HIV-l p24 antigen twice a week for~weeks.
peR. Cryopreserved PBMCs were tested by Dr. Chin-Yih Ou (Centers for Disease Control [CDC]) for the presence of HIV-l proviral DNA by PCR using the primer pair SK38/39 for the gag region of HIV-l, as described previously [16] .
HW-2 and HTLV-I serologic assays. Sera were tested by commercially available EIA kits for antibodies to HIV-2 (Genetic Systems, Seattle) and HTLV-I (Du Pont) at Johns Hopkins University. (n = 53) were similar in terms of age (mean years ± SD, 34 ± 9 vs. 32 ± 10), sex (male, 56% vs. 49%), race (white, 96 % vs. 92 %), and serologic markers for HBV (8 % vs. 5 %). The indeterminate group had the following characteristics: 85% had only bands of low intensity; 68% had a single band (p17, 6%; p24, 28%; p55, 17%; p51, 2%; p66, 15%); 32% had two or more bands (any combination of gag bands, 9 %; of pol bands, 2 %; of gag and pol bands, 17%; of gag and env bands, 2 %; of gag, pol, and env bands, 2 %). Bands corresponding to p24, p55, and p66 occurred most frequently (47%, 34%, and 36% of WBs, respectively), and those corresponding to envelope bands occurred least frequently (4%). Thirty-three (62 %) of those with indeterminate WB tests returned for follow-up within 2-11 months (mean, 7 months) (table 1). They did not differ significantly in terms of age, sex, race, or serologic markers for HBV from those with indeterminate WB tests who did not return for follow-up. Their follow-up serum samples were negative by EIA for HIV-l p24 antigen and antibodies to HIV-l, HIV-2, and HTLV-I. None had developed a positive WB test, including subject 19, who had p24 and gp41 bands detected on initial testing. At the AVEUs, the initial and follow-up serum samples from each individual were tested with different WB kit lots. Only 12 (36 %) of 33 had the same indeterminate WB pattern in both serum specimens; 8 had a different indeterminate WB pattern and 13 had a negative WB result.
To determine if this variability in test results was related to the use of different WB kit lots or intrinsic differences in serum samples from the same individual, these serum samples were simultaneously tested at the central laboratory with the same WB kit lot (table 1) . Identical results were observed in 30 (91%) of33 paired serum specimens. The reproducibility of results in paired specimens tested with different kit lots compared with those tested with the same kit lot revealed a marked discrepancy: 12 (36%) compared with 30 (91%) of 33 identical pairs (P < .001, X 2 ) .
The lot-to-lot variability of the WB results was further illustrated in a subset of four subjects who had blood collected on three different occasions over 5-7 months. Each specimen was tested multiple times by different WB kit lots at one of the AVEUs and the central laboratory. In no case was the WB pattern consistently reproduced. The serum specimens of one subject showed WB results ranging from negative to indeterminate with gag, pol, and env bands. This subject's second serum specimen showed the following results: lots 1 and 2, p24; lot 3, negative; lot 4, p24, p31, p51, p66, gp120, gp160. The last result would have met the manufacturer's criteria for positive except that the p24 band was only of +/-intensity. NOTE. Initial and follow-up serum samples were negative by EIA for HIV-1, HIV-2, and HTLV-I antibodies and for HIV-l p24 antigen; specimens from 26 were tested by HIV-I culture (n = 8), polymerase chain reaction (n = 7), or both (n = 11) and were negative. Initial and follow-up samples were tested sequentially with different WB kit lots at the AIDS vaccine evaluation units (AVEUs) and were subsequently tested simultaneously with the same WB kit lot at the central laboratory. Neg = negative. Numbers refer to proteins.
* Bands of + intensity; all other bands were of +/-intensity.
Serial serum specimens from this subject were repeatedly negative fur HIV-1 antibody and p24 antigen by EIA, and PBMCs were negative for HIV-1 by culture and PCR.
The consistency of WB results in subjects WB-negativein initial testing was also examined. Serial serum samples were collectedover7 monthsfrom 34 who received placeboor HBV vaccine in the AIDS vaccine trial. The sera were tested by different WB kit lots at both the AVEUs and centrallaboratory. The WB results for initially WB-negative individuals revealedless internalvariancethan did those for initiallyWBindeterminate subjects. Overall, 467 (98%) of 476 WB tests on 238 serum specimenswere negativeand 2 % were indeterminate. Seven had an indeterminate WB test at some point duringthe 7-monthperiod. Lot-to-lot variability mayalsohave accounted for these occasional indeterminate WB tests.
Discussion
Indeterminate WB results havebeen described in early or advanced HIV-1 infection and in the absence of infection [5] [6] [7] [8] [9] [10] [11] [12] [13] . Nevertheless, we weresurprisedthat among the volunteers for an AIDS vaccinetrial, one-third of the EIA-negative, healthy adultsat lowrisk for HIV-1 infectionhad indeterminate WB tests. One individual had a positive p24 antigen test but a negativeculture for HIV-1, suggestingthat the p24 reactivity mayhavebeen nonspecific. All 36 of the WB-indeterminate volunteers tested for HIV-1 infectionby culture, PCR, or both were negative. None of33 WB-indeterminatevolunteerswho returned for follow-up showedprogression to a positive WB, EIA, or p24 antigen test, and none was positive for antibodies to HIV-2 or HTLV-I. These data provide additional support for the CDC recommendation that individuals who have had consistently indeterminate WB tests for at least 6 months should be considered negative for HIV-1 antibodies if they have no known risk factors or clinical symptoms [5] .
The indeterminate rate of 32% in our EIA-negative volunteers was higher than the 3%-20% rates previously reported in EIA-negative volunteer blood donors [5, 6, 13] . However, the study that reported the 20% rate would most likely have had a higher rate if it had included WBs with + /-intensity bands in the indeterminate category [13] . Conversely, if we had excluded such WBs fromour indeterminatecategory, only 5 % of our volunteers would have had an indeterminate WB test. The frequencyof indeterminateWB tests in EIA-positive volunteer blood donors also has variedsignificantly, from 13% to 48% [4, 7, 10] .
Lot-to-lot variability,as described in our study,and the decision to include or excludebands of faint intensity may contribute to the variationin frequency of indeterminateWBtests. Several studies have noted that follow-up serum specimens from individuals with indeterminate WB tests often have a differentband pattern or a negative WB result. In these cases, paired serum samples were tested sequentially and therefore most likely by different WB kit lots [4, [10] [11] [12] [13] . One study that demonstrated 100% agreement in band patterns of initial and follow-up serum sampleshad tested the samplessimultaneously with the same WB kit lot [9] . The results of these studies are consistent with our finding of variability among differentlots and reproducibility within the same lot of WB kits. One exception is a study that noted poor consistency in WBband patterns of serial serum specimenseven whentested simultaneously with the same kit lot [13] .
The band composition in our study of EIA-negative, WBindeterminate subjects was similar to that reported in series of EIA-positive or EIA-negative volunteer blood donors in that most (60%-100%) indeterminate WB tests were com-posed exclusively of core bands [4, 10, 13] . The fact that we occasionally noted envelope bands is important in light of the criteria used by the Association of State and Territorial Public Health Laboratory Directors for interpretation ofWB tests. These criteria, which have been endorsed by the CDC, specify that a WB test is positive if it has any two of the following bands: p24, gp41, or gp120/160. They do not address band intensity [5] . By these criteria, WB results from three of our volunteers would have been interpreted as positive. None of these low-risk individuals had any clinical or laboratory evidence of HIV-l infection on initial or follow-up evaluation. It is important to note that these false-positive WB tests were not consistently reproducible, a phenomenon we attributed to the use of different WB kit lots.
Our experience and that of others [7] [8] [9] [10] [11] [12] [13] indicates that the overwhelming majority of indeterminate results in low-risk, EIA-negative or EIA-positive individuals are not associated with HIV-l infection. Our results have implications for both the research and clinical setting. In the area of AIDS vaccine research, we question the need to exclude low-risk volunteers on the basis of an indeterminate WB, especially if they are negative by HIV-1 culture or PCR. In the clinical setting, our findings suggest that the WB, while appropriate as a confirmatory assay for HIV-l infection in EIA-positive individuals, is not appropriate as a screening test. Furthermore, in light of the considerable lot-to-lot variability, consideration should be givento retesting serum specimens from WB-positive, lowrisk individuals by a different WB kit lot to confirm the result. 
